Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PUR1900 (inhaled itraconazole) in adult asthmatic patients with allergic bronchopulmonary aspergillosis
2018-002949-11Phase 2Terminated
- Sponsor
- Pulmatrix, Inc.
- Start
- Apr 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in allergic bronchopulmonary aspergillosis (ABPA) and asthma comparing PUR1900 (inhaled itraconazole) with Placebo inhalation (2 arms). Primary endpoint: Incidence of treatment-emergent adverse events. Started Apr 2019; status: terminated.
02
Drugs
itraconazole
03
Conditions
allergic bronchopulmonary aspergillosis (ABPA)asthma
Beyond the preview
Go deeper on 2018-002949-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002949-11.